Anhui Platuo Pharmaceutical Technology

Anhui Platuo Pharmaceutical Technology is a Chinese biotechnology company specializing in the discovery and development of innovative small molecule therapeutics for metabolic and endocrine disorders. The company focuses on multi-target agonists, particularly those targeting the GLP-1, GIP, and Glucagon receptors, to address high-prevalence conditions such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Platuo aims to leverage its internal R&D capabilities to advance candidates from preclinical discovery through clinical proof-of-concept. The firm is part of the growing cluster of life science innovators in the Anhui province of China.